of Ovarian Cancer 21st Century and Beyond卵巢癌的治疗 21世纪及展望ppt课件.ppt

下载文档 降价啦

9
0
约7.52万字
约 72页
2018-07-30 发布于贵州
举报
版权申诉
保障服务

of Ovarian Cancer 21st Century and Beyond卵巢癌的治疗 21世纪及展望ppt课件.ppt

1、本文档共72页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

of Ovarian Cancer 21st Century and Beyond卵巢癌的治疗 21世纪及展望ppt课件

* * What are some of the factors that help determine future treatment recommendations when ovarian cancer recurs? The treatment-free interval is extremely important to determine optimal therapy for recurrent disease. We also consider the impact of consolidation/maintenance therapy. Many of us continue to use paclitaxel based on the consolidation or maintenance studies. We consider the number of prior regimens and the response the patient had to these prior regimens. How fast did their CA-125 decline? What kind of toxicity did the patient experience from prior therapy? Did they require growth factor support, transfusion support, and do they have residual peripheral neuropathy? The volume and site of disease is also one of the factors. A patient who has ascites and GI symptomatology is quite different than someone whose performance status is zero and really just has a tumor marker or small volume disease. * * To detect recurrent ovarian cancer, we have several surveillance options: One could argue that a second-look laparotomy is actually a surveillance option. This is a controversial procedure, and is usually most appropriate as part of a clinical trial. The pendulum has swung away from routine use of second-look laparotomy, but it is still done occasionally. Physical examination, including pelvic exam, can help detect occult disease in the pelvis that’s not well imaged on a CT scan or other imaging modalities. CA-125 is not always a reliable marker for ovarian cancer. There can be false positive elevations or increases in CA-125, which is one of the reasons why it’s not reliable for ovarian cancer screening. In a patient with a history of ovarian cancer, particularly if their CA-125 was elevated at initial diagnosis, it can be a valuable marker that can aid in following disease. We recognize that some ovarian cancers have minimal or no CA-125 secretion. This appears to be particularly true for the non-serous histologies of ovarian cancer; clear cell, mucinous